Journal of Clinical Oncology
Articles in this Issue
Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm study.
e15562 Background: Human epidermal receptor growth factor 2 (HER2) -expressing or amplified has been identified in 2-6% of patients with stage III/IV colo...
BAT8008, a TROP-2 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1 study.
3024 Background: BAT8008 is a monoclonal ADC that delivers exatecan to cells expressing TROP-2. TROP-2 is a cell surface glycoprotein that can be expresse...
Treatment trends and survival outcomes in clinical stage III melanoma: A real-world analysis of NCDB data (2006-2022).
e21537 Background: The treatment paradigm for clinical Stage III melanoma has significantly evolved with the adoption of immunotherapy and targeted therap...
Navigating third-line therapies: A comprehensive review of regorafenib versus fruquintinib with placebo comparator for metastatic colorectal cancer—A systematic review and meta-analysis.
e15514 Background: The choice of third-line and beyond therapies for metastatic colorectal cancer (mCRC) remains uncertain. Regorafenib and Fruquintinib h...
Applications of artificial intelligence in oncology patient education: A scoping review.
e13642 Background: As cancer care becomes increasingly complex, artificial intelligence (AI) tools have the potential to improve patient understanding, pe...
Leveraging AI for validating the association between minimal residual disease (MRD) and survival outcomes in multiple myeloma.
7547 Background: Minimal residual disease (MRD) has been recently accepted by the Food and Drug Administration (FDA) as an endpoint for accelerated approv...
Age and racial disparities in esophageal cancer admissions, comorbidities, and outcomes: A nationwide analysis from 2016-2021.
e16084 Background: Esophageal carcinoma (EC) is increasingly prevalent among younger adults, particularly among Hispanics. This malignancy is driven by a...
Improving germline genetic testing in pancreatic cancer: A quality improvement project.
e16414 Background: Germline testing (GT) can provide insights into risk stratification, clinical management and potential eligibility for targeted therapi...
TeLuRide-006: An adaptive phase 2/3 study of EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, in combination with pembrolizumab in patients with advanced melanoma.
TPS9604 Background: Immune checkpoint inhibitors (ICIs) relieve immunosuppression of tumor-reactive T cells and enhance antitumor response. Significant ad...
Safety of pembrolizumab in advanced head and neck squamous cell carcinoma: A systematic review and meta-analysis of RCTs.
e14593 Background: Pembrolizumab, a checkpoint inhibitor, has demonstrated safety and efficacy in various cancers, primarily melanomas and non-small cell...
Updates to CORE-008: A phase 2 multi-arm, multi-cohort study to evaluate intravesical cretostimogene grenadenorepvec in patients with high-risk non-muscle invasive bladder cancer.
TPS4625 Background: Treatment for High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) includes Transurethral Resection of Bladder Tumor (TURBT) follow...
A phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced neuroendocrine carcinoma.
e16341 Background: ZG006 is a trispecific T cell engager (Tri-TE) targeting Delta-like ligand 3 (DLL3) and CD3, designed to bridge tumor cells and T cells...
First-in-human (FIH) phase 1 study of CUSP06, a cadherin-6 (CDH6)-directed antibody-drug conjugate (ADC), in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
3042 Background: CDH6 is a transmembrane glycoprotein involved in cancer metastasis expressed in various tumors including ovarian cancer (OC), renal cell...
Radioimmunotherapy-associated myeloid neoplasms: Real-world multicenter retrospective study using TriNetX database.
12043 Background: Radioimmunotherapy (RIT) utilizing monoclonal antibodies conjugated with therapeutic radionuclides, has emerged as a promising treatment...
Spatial profiling of solid tumor microenvironment using imaging mass cytometry with high-plex panels.
e14574 Background: Understanding cellular interactions within the tumor microenvironment (TME) is essential for elucidating disease progression and advanc...
Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: First disclosure from dose expansion cohort B2 of the GTC1184-01 study.
3039 Background: Rina-S is an investigational antibody-drug conjugate targeting folate receptor alpha with a novel hydroph...
Development and implementation of molecular oncology test e-consult at the VA North Texas Health Care System (VANTHCS).
3068 Background: The VA National Precision Oncology Program (NPOP), launched in 2016 as part of the White House’s Cancer Moonshot Initiative, aimed to rev...
Phase I/II study of DZD6008, a 4 <sup>th</sup> -generation EGFR TKI with full BBB penetration, in EGFR-mutant NSCLC.
8616 Background: NSCLC patients whose disease progressed after 3 rd generation EGFR TKI treatment often have CNS metastasis and ac...
Analysis of event-free survival (EFS) of stromal tumor infiltrating lymphocytes (sTILs), PD-L1 expression, and their early dynamics in the NeoTRIP trial.
597 Background: We demonstrated that pre-treatment sTILs and PD-L1, and on treatment sTILs but not PD-L1 were associated with pathological Complete Respon...
Artificial intelligence in genitourinary oncology: A bibliometric study and systematic review.
e16616 Background: Within the field of medicine, artificial intelligence (AI) is used to optimize diagnostic capacity, treatment planning, and prognostic...
Immunotherapy with and without radiotherapy following the diagnosis of bone metastasis for stage 4 non-small cell carcinoma.
e20574 Background: This retrospective study compared the effect of immunotherapy (IT) on survival in patients with stage 4 non-small cell lung carcinoma (...
Phase Ib study of the combination of regorafenib with conventional chemotherapy in patients with newly diagnosed multi-metastatic Ewing sarcoma: The Rego-Inter-Ewing-1 study.
10008 Background: Regorafenib monotherapy has shown interesting but limited activity against relapsed Ewing sarcoma. We present the first results of the p...
Survival for head and neck squamous cell carcinoma treated with versus without neoadjuvant systemic therapy: A national propensity score–matched analysis.
6035 Background: Neoadjuvant systemic therapies, including immunotherapy and chemotherapy, offer a promising approach for treating head and neck squamous...
Liposomal curcumin and standard radiation and temozolomide for newly diagnosed high-grade gliomas: A phase 1/2 study.
TPS2095 Background: Curcumin, derived from turmeric (Curcuma spp.), exhibits anti-inflammatory and antitumoral activity in preclinical studies, including...
The relationship between tumor mutational burden (TMB) and microsatellite instability (MSI) in biliary tract tumors and molecular background changes at different TMB thresholds.
e15167 Background: Pembrolizumab obtained FDA approval for the treatment of metastatic tumors with high mutational burden, regardless of histopathology. S...